CGC
Price
$1.09
Change
-$0.09 (-7.56%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
405.25M
85 days until earnings call
Intraday BUY SELL Signals
NBIX
Price
$144.10
Change
-$2.75 (-1.87%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
14.64B
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CGC vs NBIX

Header iconCGC vs NBIX Comparison
Open Charts CGC vs NBIXBanner chart's image
Canopy Growth
Price$1.09
Change-$0.09 (-7.56%)
Volume$179.46K
Capitalization405.25M
Neurocrine Biosciences
Price$144.10
Change-$2.75 (-1.87%)
Volume$31.82K
Capitalization14.64B
CGC vs NBIX Comparison Chart in %
View a ticker or compare two or three
VS
CGC vs. NBIX commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGC is a Hold and NBIX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (CGC: $1.19 vs. NBIX: $146.85)
Brand notoriety: CGC: Notable vs. NBIX: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CGC: 91% vs. NBIX: 121%
Market capitalization -- CGC: $405.25M vs. NBIX: $14.64B
CGC [@Pharmaceuticals: Generic] is valued at $405.25M. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $14.64B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGC’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 0 green FA rating(s).

  • CGC’s FA Score: 0 green, 5 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, NBIX is a better buy in the long-term than CGC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGC’s TA Score shows that 4 TA indicator(s) are bullish while NBIX’s TA Score has 5 bullish TA indicator(s).

  • CGC’s TA Score: 4 bullish, 7 bearish.
  • NBIX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NBIX is a better buy in the short-term than CGC.

Price Growth

CGC (@Pharmaceuticals: Generic) experienced а +4.39% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was -4.49% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

CGC is expected to report earnings on Feb 06, 2026.

NBIX is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($14.6B) has a higher market cap than CGC($405M). NBIX YTD gains are higher at: 7.582 vs. CGC (-56.569). NBIX has higher annual earnings (EBITDA): 557M vs. CGC (-410.31M). NBIX has more cash in the bank: 976M vs. CGC (144M). CGC has less debt than NBIX: CGC (328M) vs NBIX (439M). NBIX has higher revenues than CGC: NBIX (2.51B) vs CGC (275M).
CGCNBIXCGC / NBIX
Capitalization405M14.6B3%
EBITDA-410.31M557M-74%
Gain YTD-56.5697.582-746%
P/E RatioN/A35.05-
Revenue275M2.51B11%
Total Cash144M976M15%
Total Debt328M439M75%
FUNDAMENTALS RATINGS
CGC vs NBIX: Fundamental Ratings
CGC
NBIX
OUTLOOK RATING
1..100
6073
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
10058
SMR RATING
1..100
9858
PRICE GROWTH RATING
1..100
8745
P/E GROWTH RATING
1..100
10038
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (73) in the Biotechnology industry is in the same range as CGC (94) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew similarly to CGC’s over the last 12 months.

NBIX's Profit vs Risk Rating (58) in the Biotechnology industry is somewhat better than the same rating for CGC (100) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew somewhat faster than CGC’s over the last 12 months.

NBIX's SMR Rating (58) in the Biotechnology industry is somewhat better than the same rating for CGC (98) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew somewhat faster than CGC’s over the last 12 months.

NBIX's Price Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for CGC (87) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew somewhat faster than CGC’s over the last 12 months.

NBIX's P/E Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for CGC (100) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew somewhat faster than CGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGCNBIX
RSI
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
58%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
54%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 8 days ago
72%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
56%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CGC
Daily Signal:
Gain/Loss:
NBIX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MKOR33.970.10
+0.28%
Matthews Korea Active ETF
DEHP32.270.03
+0.09%
Dimensional Em Mkts High Prof ETF
GRPZ26.43N/A
N/A
Invesco S&P SmallCap 600 GARP ETF
QBUL26.13N/A
N/A
TrueShares Quarterly Bull Hedge ETF
QQQX28.01-0.10
-0.36%
Nuveen NASDAQ 100 Dynamic Overwrite Fund

CGC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGC has been closely correlated with SNDL. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if CGC jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGC
1D Price
Change %
CGC100%
-0.83%
SNDL - CGC
77%
Closely correlated
-3.24%
ACB - CGC
66%
Loosely correlated
-0.44%
TLRY - CGC
63%
Loosely correlated
-4.65%
OGI - CGC
61%
Loosely correlated
-1.83%
CRON - CGC
58%
Loosely correlated
+0.79%
More

NBIX and

Correlation & Price change

A.I.dvisor tells us that NBIX and CGC have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and CGC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
-0.30%
CGC - NBIX
33%
Poorly correlated
-0.83%
TEVA - NBIX
32%
Poorly correlated
+2.79%
EOLS - NBIX
31%
Poorly correlated
+4.43%
AQST - NBIX
30%
Poorly correlated
-1.93%
ELAN - NBIX
28%
Poorly correlated
-3.54%
More